S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.54
+1.86
+11.15%
CHRS · Coherus Oncology, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Coherus Oncology Inc (CHRS)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$1.02
+0.01
(+0.49%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.02
$1.00
$1.04
52-WEEK RANGE
$1.02
$0.94
$2.62
What's happening
- CHRS is up 0.49% today, trading at $1.02. — Live quote
- Volume today (56,268) is well below its 3-month average of 1,183,590. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.13 actual vs. $-0.20 estimated (+36.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 6
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CHRS
-28.17%
vs S&P 500
-41.54%
1-YEAR RETURN
CHRS
-41.38%
vs S&P 500
-56.54%
6-MONTH RETURN
CHRS
-48.48%
3-MONTH RETURN
CHRS
-28.67%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.13
Est. $-0.20
BEAT +36.3%
2026-04-26 (Q1 2026)
$-0.25
Est. $-0.28
BEAT +10.3%
2026-01-26 (Q4 2025)
$-0.34
Est. $-0.35
BEAT +2.9%
2025-10-26 (Q3 2025)
$-0.33
Est. $-0.33
BEAT +0.5%
Valuation Measures & Ratios
Enterprise Value4$123.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)3.03
Price / Book73.55
EV4 / Revenue2.42
EV4 / EBITDA2.14
Profit Margin-259.41%
Operating Margin-311.56%
Return on Equity (ROE8)-183.36%
Return on Assets (ROA9)-42.90%
Avg Volume (3M)1,183,590
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $221.4M | $232.7M | $188.0M | $84.6M | — |
| P/E | 1.09 | 1.39 | 0.96 | 0.39 | — |
| Price/Book | 3.64 | 2.96 | 2.14 | 0.71 | — |
| EV/EBITDA | — | — | -0.47 | — | — |
| ROE | 334.13% | 212.84% | 222.07% | 181.53% | — |
| ROA | 106.33% | 62.90% | 37.74% | 49.50% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short23,337,539
Change from Prior Settlement+2.14%
% of Float—
Days to Cover (Short Ratio)12.53
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 39.5% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-08-28; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -259.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is -41.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CHRS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$32.3M | -$36.2M | -$44.3M | -$45.5M | -$45.4M | -$46.9M | -$39.6M | -$67.8M |
| Net income | -$20.6M | -$38.3M | -$35.5M | $297.8M | -$56.6M | -$10.8M | -$12.9M | $102.9M |
| EPS (diluted) | $-0.13 | $-0.28 | $-0.31 | $2.57 | $2.57 | $-0.09 | $-0.11 | $0.91 |
| EPS (basic) | $-0.13 | $-0.28 | $-0.31 | $2.57 | $-0.49 | $-0.09 | $-0.11 | $0.91 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $191.2M | $266.0M | $258.3M | $516.5M | $439.5M | $371.1M | $448.5M | $505.0M |
| Total liabilities | $130.3M | $187.4M | $197.3M | $428.7M | $319.6M | $554.5M | $580.5M | $593.0M |
| Stockholders' equity | $60.8M | $78.6M | $61.0M | $87.8M | $119.8M | -$183.5M | -$132.0M | -$88.0M |
| Total current assets | $133.8M | $206.0M | $206.7M | $461.0M | $380.2M | $310.2M | $341.6M | $369.0M |
| Total current liabilities | $75.5M | $132.3M | $140.4M | $372.3M | $263.6M | $255.0M | $283.0M | $295.6M |
| Cash & equivalents | $82.9M | $115.2M | $88.9M | $103.4M | $216.9M | $82.4M | $126.0M | $97.7M |
| Marketable securities (current) | $22.4M | $51.8M | $83.2M | $88.3M | $20.7M | — | — | — |
| Accounts receivable | $13.9M | $22.1M | $17.8M | $9.2M | $5.1M | $60.5M | $111.3M | $167.6M |
| Inventory | $5.7M | $4.8M | $3.2M | $2.0M | $4.5M | $3.5M | $4.2M | $47.6M |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | — | — | $1.3M | $1.6M | $1.9M | $2.3M | $2.6M | $2.9M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible assets | $18.8M | $19.4M | $20.0M | $20.6M | $23.5M | $24.1M | $24.8M | $25.5M |
| Other non-current assets | $3.1M | $3.6M | $4.1M | $4.4M | $5.0M | $5.7M | $6.5M | $7.4M |
| Accounts payable | $13.2M | $11.5M | $9.9M | $24.9M | $37.6M | $40.9M | $28.5M | $21.9M |
| Accrued liabilities | $14.9M | $15.2M | $20.4M | $13.1M | $14.2M | $46.3M | $60.3M | $61.0M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $17.6M | $17.0M | $19.9M | $17.5M | $16.7M | $31.3M | $29.3M | $29.2M |
| Common stock & paid-in capital | $15.0K | $15.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K | $12.0K |
| Retained earnings | -$1.44B | -$1.42B | -$1.38B | -$1.35B | -$1.31B | -$1.61B | -$1.55B | -$1.50B |
| Accumulated other comprehensive income (loss) | -$281.0K | -$268.0K | -$195.0K | -$203.0K | -$275.0K | -$275.0K | -$275.0K | -$275.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$62.1M | -$57.9M | -$19.7M | -$46.3M | -$46.6M | -$25.8M | $28.6M | -$62.0M |
| Investing cash flow | $29.6M | $30.7M | -$2.8M | -$67.2M | $462.6M | -$17.5M | -$542.0K | $444.0K |
| Financing cash flow | $144.0K | $53.6M | $8.1M | $2.0K | -$281.5M | -$264.0K | $231.0K | -$167.0K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Depreciation & amortization | — | — | $900.0K | $300.0K | $300.0K | $400.0K | $1.0M | $400.0K |
| Share-based compensation | $2.6M | $2.4M | $2.8M | $3.4M | $5.4M | $5.4M | $6.4M | $6.9M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in inventory | -$437.0K | $11.3M | $1.1M | -$2.5M | -$3.8M | $22.2M | $6.5M | $6.9M |
| Change in accounts payable | — | — | — | — | — | — | — | — |
| Purchases of investments | $13.9M | $6.4M | $14.3M | $68.8M | $20.7M | — | — | — |
| Sales/maturities of investments | — | — | — | — | — | — | $0 | $0 |
| Other investing activities | $8.0K | $1.1M | $12.0K | $27.0K | $36.0K | $267.0K | $542.0K | -$444.0K |
| Share repurchases | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $0 | $112.0K | $0 | $3.0K | $16.0K | $264.0K | $10.0K | $10.0K |
| Other financing activities | $63.0K | $52.0K | $22.0K | $5.0K | -$859.0K | — | $0 | -$7.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | -$181.1M | -$199.7M | -$203.2M | -$256.9M | -$263.9M |
| Net income | $168.0M | $28.5M | -$237.9M | -$291.8M | -$287.1M |
| EPS (diluted) | $1.43 | $0.25 | $-2.53 | $-3.76 | $-3.81 |
| EPS (basic) | $1.43 | $0.25 | $-2.53 | $-3.76 | $-3.81 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $258.3M | $448.5M | $629.6M | $480.8M | $679.3M |
| Total liabilities | $197.3M | $580.5M | $823.0M | $618.3M | $581.6M |
| Stockholders' equity | $61.0M | -$132.0M | -$193.4M | -$137.4M | $97.7M |
| Total current assets | $206.7M | $341.6M | $475.6M | $381.2M | $602.3M |
| Total current liabilities | $140.4M | $283.0M | $331.8M | $138.7M | $165.3M |
| Cash & equivalents | $88.9M | $126.0M | $102.9M | $63.5M | $417.2M |
| Marketable securities (current) | $83.2M | — | $14.9M | $128.1M | — |
| Accounts receivable | $17.8M | $111.3M | $260.5M | $110.0M | $123.0M |
| Inventory | $3.2M | $4.2M | $62.6M | $38.8M | $37.6M |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $1.3M | $2.6M | $5.1M | $8.8M | $7.8M |
| Goodwill | — | — | $943.0K | $943.0K | $900.0K |
| Intangible assets | $20.0M | $24.8M | $41.9M | $2.4M | — |
| Other non-current assets | $4.1M | $6.5M | $9.7M | $8.7M | $10.0M |
| Accounts payable | $9.9M | $28.5M | $35.2M | $11.5M | $16.2M |
| Accrued liabilities | $20.4M | $60.3M | $105.4M | $50.1M | $48.1M |
| Deferred revenue (current) | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Other non-current liabilities | $18.4M | $29.3M | $12.6M | $3.5M | $750.0K |
| Common stock & paid-in capital | $12.0K | $12.0K | $11.0K | $8.0K | $7.0K |
| Retained earnings | -$1.38B | -$1.55B | -$1.58B | -$1.34B | -$1.05B |
| Accumulated other comprehensive income (loss) | -$195.0K | -$275.0K | -$248.0K | -$249.0K | -$270.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$138.5M | -$20.4M | -$174.9M | -$241.1M | -$37.4M |
| Investing cash flow | $375.1M | $230.3M | $144.6M | -$166.8M | -$138.4M |
| Financing cash flow | -$273.7M | -$187.0M | $69.6M | $54.3M | $51.9M |
| Free cash flow | — | — | -$175.2M | -$243.2M | -$38.7M |
| Capital expenditures | — | — | $286.0K | $2.0M | $1.3M |
| Depreciation & amortization | $1.3M | $1.6M | $3.2M | $3.6M | $3.5M |
| Share-based compensation | $17.0M | $27.8M | $43.1M | $50.7M | $51.4M |
| Deferred income taxes | — | — | -$380.0K | — | — |
| Change in accounts receivable | — | — | — | — | — |
| Change in inventory | $17.1M | $32.0M | $46.7M | $47.3M | $6.3M |
| Change in accounts payable | — | — | — | — | — |
| Purchases of investments | $103.8M | — | $19.5M | $127.4M | $182.5M |
| Sales/maturities of investments | — | $8.7M | $13.3M | — | $81.7M |
| Other investing activities | $342.0K | -$110.0K | $492.0K | $4.5M | — |
| Share repurchases | — | — | — | — | — |
| Tax withholding on stock comp | $283.0K | $2.5M | $3.6M | $3.7M | $1.8M |
| Other financing activities | -$832.0K | $43.0K | -$1.0M | -$1.2M | -$672.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CHRS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-01-20 to 2026-06-05
Recent transactions
- Most recent: Satvat Ali J. (Reporting person) — Grant / award of 30,000 shares on 2026-06-05.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Satvat Ali J. | Reporting person | Grant / award | 2026-06-05 | 30,000 |
| Karachun Rita A | Reporting person | Grant / award | 2026-06-05 | 30,000 |
| Newcomer Lee Nisley | Reporting person | Grant / award | 2026-06-05 | 30,000 |
| Ryan Michael Lee | Reporting person | Grant / award | 2026-06-05 | 30,000 |
| O'Donnell-Tormey Jill | Reporting person | Grant / award | 2026-06-05 | 30,000 |
| Wahlstrom Mats | Reporting person | Grant / award | 2026-06-05 | 30,000 |
| Newton Charles W. | Reporting person | Grant / award | 2026-06-05 | 30,000 |
| Lanfear Dennis M | President & CEO | Grant / award | 2026-01-23 | 375,000 |
| McMichael Bryan J | Chief Financial Officer | Grant / award | 2026-01-22 | 112,500 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-05 | Satvat Ali J. | Reporting person | Grant / award | 30,000 | $0.00 |
| 2026-06-05 | Karachun Rita A | Reporting person | Grant / award | 30,000 | $0.00 |
| 2026-06-05 | Newcomer Lee Nisley | Reporting person | Grant / award | 30,000 | $0.00 |
| 2026-06-05 | Ryan Michael Lee | Reporting person | Grant / award | 30,000 | $0.00 |
| 2026-06-05 | O'Donnell-Tormey Jill | Reporting person | Grant / award | 30,000 | $0.00 |
| 2026-06-05 | Wahlstrom Mats | Reporting person | Grant / award | 30,000 | $0.00 |
| 2026-06-05 | Newton Charles W. | Reporting person | Grant / award | 30,000 | $0.00 |
| 2026-01-23 | Lanfear Dennis M | President & CEO | Grant / award | 375,000 | $0.00 |
| 2026-01-22 | McMichael Bryan J | Chief Financial Officer | Grant / award | 112,500 | $0.00 |
| 2026-01-20 | McMichael Bryan J | Chief Financial Officer | Tax withholding | 1,715 | $1.55 |
| 2026-01-20 | Lanfear Dennis M | President & CEO | Tax withholding | 11,839 | $1.55 |
| 2025-05-23 | Wahlstrom Mats | Reporting person | Open market sale | 99,988 | $0.74 |
| 2025-01-20 | McMichael Bryan J | Chief Financial Officer | Tax withholding | 1,711 | $1.39 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:15 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-28 | 8-K | 2026-08-28 | View on SEC.gov → |
| 2026-08-17 | 8-K | 2026-08-17 | View on SEC.gov → |
| 2026-08-17 | 8-K | 2026-08-17 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-06-15 | 8-K | 2026-06-12 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
| 2026-06-09 | 4 | 2026-06-05 | View on SEC.gov → |
Recent news
Headlines about CHRS (Coherus Oncology, Inc.). Links open the publisher — we don’t host full articles.
-
Coherus schedules October 28 webcast for Coherus Oncology stock
AD HOC NEWS · 2026-10-20 -
Coherus Oncology schedules October 28 webcast for Coherus Oncology stock
AD HOC NEWS · 2026-10-17 -
Coherus Oncology stock sits at EUR 0.93 with a price-to-earnings ratio of -1.02 - ad-hoc-news.de
ad-hoc-news.de · 2026-10-15 -
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Yahoo · 2026-10-14 -
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Yahoo Finance · 2026-09-23 -
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha · 2026-09-16 -
Coherus to Participate in Upcoming Investor Conferences
Yahoo Finance · 2026-08-31 -
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development
Seeking Alpha · 2026-08-19
No headlines in this category right now — try “All”.